MedTrace Logo

Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

NCT04242238 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-08-28

No results posted yet for this study

Summary

This study is being done to find the safest dose of DCC-3014 that can be given with avelumab to participants with advanced or metastatic sarcomas that will not cause serious side effects.

Conditions

Interventions

DRUG

DCC-3014

DCC-3014 will be administered in pill form. Start Day 1 on first cycle and continue with dosing of DCC-3014.

DRUG

Avelumab

Start Day 1 on first cycle with further infusions of avelumab every 14 days

Sponsors & Collaborators

Principal Investigators

  • Sandra D'Angelo, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-22
Primary Completion
2025-08-26
Completion
2025-08-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04242238 on ClinicalTrials.gov